MUC1 and COVID-19: Because KL-6 is a glycoprotein released by the type II alveolar pneumocytes and bronchial epithelial cells in various pulmonary diseases [30], the injury of pneumocytes and alveoli in COVID-19 may be pathophysiologically associated with elevated levels of KL-6 in the blood [31].